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Intensive vs. moderate lipid lowering with statins after acute coronary
syndrome
Cannon CP, Bromwald E, McCabe CH, et al. New Engl J Med 2004;350:
1495-504.
Conclusion: Patients with a recent acute coronary syndrome have
greater protection against major cardiovascular events and death when
treated with an intensive lipid-lowering statin regimen versus a standard
statin regimen.
Summary: The study enrolled 4,162 patients hospitalized for acute
coronary syndrome. Enrollment occurred within 10 days of hospitalization.
The patients received standard medical management including aspirin at
dosages of 75 to 325 mg daily with or without clopidogrel or warfarin. They
were randomized with a 1 to 1 allocation scheme to receive either 40 mg of
pravastatin daily (standard therapy) or 80 mg of atorvastatin daily (intensive
therapy). The primary end point was a composite of death from any cause,
unstable angina, myocardial infarction, stroke, and revascularization per-
formed at least 30 days after randomization. Follow-up was from 18 to 36
months (mean, 24 months).
Median low-density lipoprotein (LDL) cholesterol level achieved dur-
ing treatment was 95 mg/dL in the standard-dose pravastatin group and 62
mg/dL in the intensive-dose atorvastatin group (P  .001). The rates of
primary end points at 2 years determined by Kaplan-Meier estimates were
26.3% in the pravastatin group and 22.4% in the atorvastatin group; a 16%
decrease in the hazard ratio in favor of the intensive-therapy atorvastatin
group (P  .005; 95% confidence interval, 5-26%).
Comment: Previous studies have indicated standard dose statin ther-
apy is beneficial. The Heart Protection Study, in which statin treatment
resulted in an LDL cholesterol level that was 40 mg/dL lower than the
placebo group, was accompanied by 25% reduction in cardiovascular events.
This study demonstrates that even more intensive lipid lowering increases
benefit further. The implications are profound and the study likely marks a
new era of intensive statin therapy.
Sex differences in carotid plaque and stenosis
Iemolo F, Martiniuk A, Steinman DA, Spence JD. Stroke 2004;35:477-81.
Conclusion: Carotid plaque area is a greater predictor of stroke,
myocardial infarction, and death than carotid stenosis.
Summary: Experimental and epidemiologic evidence suggests estro-
gen may have beneficial effects on endothelial function and development of
atherosclerosis. This raises the possibility of sex differences in arterial remod-
eling. Sex differences were evaluated in carotid plaque area and stenosis with
respect to survival free of stroke, death, and myocardial infarction. The
authors studied 1,686 patients followed in a premature atherosclerosis and
stroke prevention clinic associated with the London Health Sciences Center
in London, Ontario, Canada. A total of 1,686 patients were followed
annually for up to 5 years (mean, 2.5  1.3 years). Carotid plaque area was
determined by using high-resolution duplex ultrasound. Carotid stenosis
was determined by Doppler peak frequency measurements calibrated against
angiography. Cardiovascular events were ascertained by questionnaire at
annual visits, by review of hospital charts, and by contact with families and
family physicians.
During follow-up, there were 45 strokes, 94 myocardial infarctions,
and 41 deaths. Carotid stenosis and plaque increased with age. Overall,
women had greater stenosis compared with men (P  .001), but men had
greater plaque area than women at all ages (P  .001). The combination of
stroke, myocardial infarction, and death in the total population was pre-
dicted by carotid artery plaque area (P  .004), but not by carotid artery
stenosis (P  .42). When sexes were analyzed separately, plaque area was a
significant predictor of stroke, myocardial infarction, or death for women
(P .028) and approached significance for men (P .06). Stenosis did not
predict the combined outcome of stroke, myocardial infarction, and death
for men (P  .84) or women (P  .20).
Comment: It is perplexing why stroke, myocardial infarction, and
death were not predicted by carotid stenosis. Perhaps carotid plaque area is
a better measure of the overall burden of atherosclerosis than carotid artery
stenosis. In that regard, it would have been interesting if the authors had
included other measures of atherosclerosis, such as the ankle brachial index,
in their study. The study raises the interesting question as to whether
vascular laboratories should consider measurement of total plaque burden
during assessment of the carotid bifurcation.
Factor V Leiden and the risk for venous thromboembolism in the adult
Danish population
Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Ann Intern Med
2004;140:330-7.
Conclusion: In patients with the Factor V Leiden genotype, smoking,
obesity and old age result in an absolute 10-year thromboembolic risk of
10% in heterozygotes and 51% in homozygotes.
Summary: The authors sought to determine hazard ratios for venous
thromboembolism (VTE) in Factor V Leiden heterozygotes and homozy-
gotes. In addition, they sought to determine whether hazard ratios differed
for deep venous thrombosis (DVT) or pulmonary embolism (PE), and to
estimate absolute risk for VTE according to Factor V Leiden genotype and
the presence, or absence, of other VTE risk factors. This was a cohort study
with 23 years of follow-up of 9,253 randomly selected individuals from the
adult Danish population. Hospitalization, death from VTE, Factor V Leiden
genotype, and additional thrombotic risk factors were assessed. Adjusted
hazard ratios in heterozygotes and homozygotes, compared with noncarri-
ers, were 2.7 (95% confidence interval [CI], 1.8-3.8) and 18 (CI, 4.1-41)
respectively for VTE overall. For DVT, adjusted hazard ratios in heterozy-
gotes and homozygotes compared with noncarriers were 2.4 (CI, 1.3-3.8)
and 22 (CI, 0-60). For PE, hazard ratios were 3.0 (CI, 1.7-4.9) for
heterozygotes and 11 (CI, 0-33) for homozygotes. The highest absolute
10-year VTE risk for heterozygotes was 10% (CI, 7%-14%) in smokers older
than 60 years of age with a body mass index of 30kg/m2. In homozygotic
smokers older than 60 years of age with body mass indexes above 30kg/m2,
the absolute 10-year VTE risk was 51%.
Comment: The article reinforces the fact that risk factors for VTE are
not linearly additive. Risk is basically exponential. Individual risk factors for
VTE somehow act in synergy with the overall risk in a patient, with multiple
risk factors for VTE being considerably higher than would be predicted by
the individual contribution of each risk factor.
C-Reactive protein and other circulating markers of inflammation in
the prediction of coronary heart disease
Danesh J, Phil D, Wheeler JG, et. al. New Engl J Med 2004;350:1387-97.
Conclusion: C-Reactive protein (CRP) is only a moderate predictor of
coronary heart disease. Established risk factors, such as increased total
cholesterol and cigarette smoking, are stronger predictors of coronary heart
disease.
Summary: CRP is an acute-phase reactant binding capsular pneumo-
coccal polysaccharide. It is a very highly sensitive marker of inflammation
and is principally produced in hepatocytes. Its expression is induced by
cytokines, especially interleukin-6. Recent publications have suggested CRP
is a strong marker for risk of coronary events (Circulation 2003;107:499;
New Engl J Med 1997;337:356).
This was a prospective study based in Reykjavik, Iceland. The authors
obtained information regarding CRP levels, erythrocyte sedimentation
rates, von Willebrand factor concentration, cholesterol levels, and cigarette
smoking in 2449 patients who had a non-fatal myocardial infarction or died
of coronary disease, and from 3969 controls without coronary disease. There
were a total of 18,569 participants in the study. Measurements were also
made in paired samples obtained from 379 participants an average of 12
years apart in order to quantify within-person fluctuations of inflammatory
marker levels.
The within-person correlation coefficient for long-term stability of
CRP values was 0.59, 95% confidence interval (CI), 0.52-0.66. This was
similar to blood pressure and total serum cholesterol. After adjusting for
baseline values of established risk factors, the odds ratio for coronary heart
disease was 1.45, 95% CI 1.25-1.68, comparing participants in the top third
of the group with respect to baseline CRP levels with those in the bottom
third. There were similar overall findings in an updated meta-analysis of
7068 patients with coronary heart disease. Compared with the association
between coronary heart disease and CRP, odds ratios in the Reykjavik study
were weaker for association of coronary heart disease with erythrocyte
sedimentation rate (1.30; 95% CI, 1.13-1.51) and von Willebrand factor
concentration (1.11; 95% CI, 0.97-1.27). Odds ratio for established risk
factors were stronger than that for CRP. The odds ratio for increased total
cholesterol concentration was 2.35 (95% CI, 2.03-2.74) while that for
cigarette smoking was 1.87 (95% CI, 1.62-2.16).
Comment: These findings confirm original work showing that CRP
levels are an indicator of increased risk for coronary heart disease. The
current findings do, however, call into question the magnitude of the risk. It
is not unusual for original publications to overestimate effects that are later
400
more thoroughly evaluated and updated in larger studies. Although the
relevance of CRP measurements in the prediction of risk of coronary heart
disease is not completely clear, research in this area has definitely sparked
interest in the inflammatory underpinnings of atherosclerosis.
Effect of an inhibitor of cholesteryl ester transfer protein on HDL
cholesterol
Brousseau ME, Schaefer EJ, Wolfe ML, et al. New Engl J Med 2004;350:
1505-15.
Conclusion: Torcetrapid, a potent inhibitor of cholesteryl ester trans-
fer protein (CETP), dramatically increases high-density lipoprotein (HDL)
cholesterol levels and also decreases low-density lipoprotein (LDL) choles-
terol levels in subjects with low HDL cholesterol levels. The effect is the
same when torcetrapid is administered alone or in combination with a statin.
Summary: This was a single-blind, placebo-controlled study examin-
ing the effects of torcetrapid on plasma lipoprotein levels in people with low
HDL cholesterol levels. There were 19 subjects with HDL levels
40mg/dL in the study. Nine of the 19 subjects were also treated with 20
mg of atorvastatin daily. All 19 subjects received placebo for 4 weeks and
then received 120 mg of torcetrapid daily for 4 weeks. Six subjects who did
not receive atorvastatin participated in a third phase of the trial, in which they
received 120 mg of torcetrapid twice daily for 4 weeks.
In the atorvastatin and non-atorvastatin cohorts treatment with 120
mg of torcetrapid daily increased HDL levels by 61% (P  .001) and 46%
(P  .001) respectively. Treatment with 120 mg of torcetrapid twice daily
increased HDL by 106% (P .001). In the atorvastatin cohort, torcetrapid
also decreased LDL cholesterol levels by 17% (P  .02). Torcetrapid also
altered the distribution of cholesterol among LDL and HDL subclasses,
resulting in increases in the mean particle size of LDL and HDL in each
cohort tested.
Comment: HDL serves as a carrier of excess cellular cholesterol in the
reverse cholesterol transport pathway and thus is believed to provide protec-
tion against development of atherosclerosis. Two different approaches cur-
rently exist to increasing HDL levels. One is infusion of apoA-1 Milano
along with phospholipids (JAMA 2003;290:2292-300). The second is use
of CETP inhibitors as illustrated in this study. Preliminary results of both
methods appear promising. Additional clinical trials will be required to
confirm efficacy of both methods of raising HDL cholesterol levels, to select
dosages for clinical use, and to establish whether medication induced eleva-
tions of HDL levels will protect against cardiovascular disease.
Late complications after ligation and bypass for popliteal aneurysm
Kirkpatrick UJ, McWilliams RG, Martin J, et al. Brit J Surg 2004;91:174-7.
Conclusion: Ligation and bypass does not always abolish flow in the
sac of a popliteal aneurysm. Continued flow in the aneurysm sac may be
associated with aneurysm expansion and late complications.
Summary: This study was a retrospective review of patients who
underwent popliteal aneurysm repair in a university hospital over a 10-year
period. Only patients with atherosclerotic aneurysms were included. Forty-
four patients (43 males, median age 72 years) were identified who had
undergone 53 primary popliteal aneurysm repairs. Seventeen popliteal an-
eurysm repairs were excluded because of primary repair with an in-line graft,
loss to follow-up, and amputation or death, leaving available for study 36
popliteal aneurysms treated by ligation and bypass in 30 patients. Patients
were brought back for ultrasound examination. Median interval from oper-
ative repair to follow up duplex ultrasound imaging was 59 (range, 1-120)
months. A significant change in aneurysm diameter between the initial
preoperative measurement and that on follow-up imaging was defined as a
diameter increase greater than 5 mm or a change greater than 20%.
Twenty-four of the 36 bypassed popliteal aneurysms did not demon-
strate any intrasac flow on duplex examination. Ten of these were known to
be thrombosed at initial presentation. Intrasac blood flow was demonstrated
with duplex imaging in 12 popliteal aneurysms at a median of 48 (range,
13-100) months following primary bypass and ligation. Eight of these 12
aneurysms with intrasac flow by duplex scanning demonstrated significant
increase in size by the criteria noted above. One 8-cm aneurysm ruptured
with the rupture occurring 54 months after primary ligation and bypass of a
3-cm popliteal aneurysm.
Comment: The study demonstrates that patent popliteal aneurysms
treated by ligation and bypass are at significant risk of delayed complications.
Persistent blood flow within the aneurysm sac occurs in nearly half of
patients. The data suggests patients with popliteal aneurysms treated by
ligation and bypass require follow-up duplex studies to confirm thrombosis
of the aneurysm sac.
Association between high serum ferritin levels in carotid atherosclerosis
in the study of health in Pomerania (SHIP)
Wolff B, Volzke H, Ludemann J, et al. Stroke 2004;35:453-7.
Conclusion: There is a relationship between serum ferritin levels and
carotid atherosclerosis that is potentiated by low-density lipoprotein (LDL)
cholesterol.
Summary: Epidemiologic studies have observed an association be-
tween iron stores and myocardial infarction (Circulation 1992;86:803-811;
Circulation 1994;89:102-8). Iron is reportedly proatherogenic because of
its ability to generate reactive oxygen species, oxidize lipoproteins, and
activate platelets. To investigate the relationship between body iron load and
cardiovascular disease, the authors assessed intima-media thickness and
plaque prevalence in carotid arteries, using high-resolution ultrasound.
There were 2443 participants in the study (1200 women; age 45-79 years).
Multivariable analysis indicated serum ferritin levels were not indepen-
dently associated with carotid intima-media thickness in men or women.
There was a relationship between serum ferritin levels and carotid plaque
prevalence among men but not women (odds ratio per 1-SD increase of
serum ferritin levels, 1.33; 95% confidence interval, 1.08-1.44 for men).
Both men and women did show a dose response relationship between serum
ferritin levels and carotid atherosclerosis. Higher serum ferritin levels were
associated with greater odds ratios for carotid plaque prevalence. In men the
association of serum ferritin levels with carotid plaque prevalence became
stronger with increasing LDL cholesterol levels.
Comment: The study demonstrated a synergistic relationship in which
the magnitude of association between serum ferritin levels and carotid
atherosclerosis becomes greater with higher LDL cholesterol levels. This
suggests some mechanism whereby iron interferes with lipid metabolism.
While there is a certain level of biologic plausibility to such an interaction,
the overall data supporting a relationship between serum ferritin levels and
atherosclerosis still seems a bit weak. Any relationship is likely to be over-
whelmed by the effects of more traditional risk factors such as hypercholes-
terolemia, smoking and diabetes.
Major lower extremity amputation: Outcome of a modern series
Aulivola B, Hile CN, Hamdan AD, et al. Arch Surg 2004;139:395-9.
Conclusion: Major amputation of the lower extremity continues to
result in significant morbidity and mortality. Long-term survival is dismal in
patients with diabetes and end-stage renal disease requiring above-knee
amputation (AKA).
Summary: This was a retrospective analysis of 959 consecutive major
lower extremity amputations performed in 788 patients at an academic
tertiary care medical center from Jan 1, 1990, to Dec 31, 2001. Mean
follow-up was 33.6 months. The data was analyzed for patient survival,
operative morbidity, and re-amputation.
There were 704 below-knee amputations (BKAs) and 255 AKAs
performed. The overall 30-day mortality was 8.6% and was worse for AKA
(16.5%) than BKA (5.7%), P  .001. Patients requiring guillotine amputa-
tion to control sepsis had a higher mortality rate than patients undergoing
closed amputation (14.3% vs 7.8%, P  .03). Cardiac complications oc-
curred in 10.2% of patients and wound infections occurred in 5.5% of
patients. Re-operation was required in 4.7% of AKAs and 18.4% of BKAs.
Sixty-six of 129 re-operated BKAs required conversion to an AKA. Patient
survival at 1 and 5 years was 69.7% and 34.7% overall. Patients undergoing
AKA had worse survival than those undergoing BKA (50.6% vs 74.5% at 1
year and 22.5% vs 37.8% at 5 years, P  .001). Five-year survival in patients
with diabetes was 30.9% vs 51.0% in patients without diabetes, P  .002).
Five-year survival in patients with end-stage renal disease was 14.4% versus
42.2% in patients without renal failure.
Comment: This article is sobering in that it quantifies the dismal
prognosis of a group of patients who can best be described as approaching
the end of life. While the numbers are interesting, it would have been so
much more interesting to know how many patients successfully achieved
independent ambulation, how long it took to achieve complete wound
healing, and what percentage of the time of the patients’ remaining life were
they independent and able to ambulate.
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